PriceTargets.com logo

AstraZeneca - AZN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $89.75
  • Forecasted Upside: 37.34%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 2 Strong Buy Ratings
$65.35 As of 12/20/2024 06:51 PM ET
▲ +0.91 (1.41%)

This chart shows the closing price for AZN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AstraZeneca Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AZN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AZN

Analyst Price Target is $89.75
▲ +37.34% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is $89.75, with a high forecast of $97.00 and a low forecast of $82.00. The average price target represents a 37.34% upside from the last price of $65.35.

This chart shows the closing price for AZN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 investment analysts is to moderate buy stock in AstraZeneca. This rating has held steady since March 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 2 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/21/2024
  • 2 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 2 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2024UBS GroupUpgradeSell ➝ Neutral
11/6/2024Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold
9/13/2024Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell
9/11/2024Erste Group BankUpgradeHold ➝ Buy
8/12/2024TD CowenBoost TargetBuy ➝ Buy$90.00 ➝ $95.00
6/24/2024CitigroupUpgradeStrong-Buy
6/24/2024BarclaysUpgradeStrong-Buy
5/30/2024ArgusBoost TargetBuy ➝ Buy$80.00 ➝ $85.00
5/30/2024The Goldman Sachs GroupInitiated CoverageBuy$97.00
4/26/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$80.00 ➝ $82.00
4/16/2024Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold
2/8/2024Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell
1/23/2024Morgan StanleyInitiated CoverageOverweight
1/3/2024Jefferies Financial GroupDowngradeBuy ➝ Hold
12/18/2023HSBCInitiated CoverageBuy
9/25/2023Jefferies Financial GroupUpgradeHold ➝ Buy
9/8/2023Erste Group BankReiterated RatingBuy ➝ Hold
7/14/2023HSBCInitiated CoverageBuy
7/12/2023UBS GroupUpgradeNeutral ➝ Buy
7/4/2023Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
5/26/2023ArgusLower Target$85.00 ➝ $80.00
4/11/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight
1/18/2023Berenberg BankBoost TargetGBX 118 ➝ GBX 126
1/5/2023BMO Capital MarketsInitiated CoverageOutperform
10/19/2022Berenberg BankLower TargetGBX 120 ➝ GBX 118
9/15/2022Credit Suisse GroupDowngradeOutperform ➝ Neutral
9/7/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight
8/29/2022ArgusUpgradeHold ➝ Buy
8/22/2022AlphaValueUpgradeReduce
6/14/2022UBS GroupDowngradeBuy ➝ Neutral
5/24/2022DanskeInitiated CoverageBuy
5/18/2022Kepler Capital MarketsDowngradeBuy ➝ Hold
2/28/2022Stifel NicolausInitiated CoverageBuy
2/24/2022Leerink PartnersBoost TargetOutperform$65.00 ➝ $70.00
2/11/2022DZ BankUpgradeSell ➝ Hold
12/12/2021Leerink PartnersReiterated RatingBuy
12/7/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$54.00
11/29/2021Morgan StanleyReiterated RatingOverweight
11/22/2021Bryan, Garnier & CoDowngradeBuy
10/19/2021UBS GroupReiterated RatingBuy
10/11/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
9/27/2021Leerink PartnersBoost TargetOutperform$71.00 ➝ $73.00
9/20/2021Leerink PartnersBoost TargetOutperform$69.00 ➝ $71.00
9/17/2021Morgan StanleyReiterated RatingOverweight
8/12/2021JPMorgan Chase & Co.Initiated CoverageOverweight
8/9/2021Morgan StanleyInitiated CoverageOverweight
8/4/2021Leerink PartnersBoost TargetOutperform$63.00 ➝ $69.00
7/21/2021CitigroupReiterated RatingBuy
7/16/2021Leerink PartnersLower TargetOutperform$64.00 ➝ $63.00
6/17/2021UBS GroupReiterated RatingBuy
6/4/2021Leerink PartnersBoost TargetOutperform$63.00 ➝ $64.00
4/19/2021ArgusReiterated RatingBuy ➝ Hold
4/12/2021ArgusDowngradeBuy ➝ Hold
3/23/2021Societe GeneraleReiterated RatingBuy
3/18/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
3/16/2021Jefferies Financial GroupUpgradeHold ➝ Buy
3/9/2021Berenberg BankReiterated RatingBuy
3/8/2021BarclaysReiterated RatingOverweight
3/2/2021Leerink PartnersLower TargetOutperform$64.00 ➝ $63.00
2/25/2021UBS GroupUpgradeNeutral ➝ Buy
1/22/2021BarclaysReiterated RatingOverweight
1/15/2021Berenberg BankReiterated RatingBuy
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy
12/30/2020AlphaValueUpgradeReduce
12/14/2020UBS GroupReiterated RatingPositive
12/13/2020Piper SandlerLower TargetOverweight$179.00 ➝ $175.00
12/7/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight
11/30/2020UBS GroupUpgradeSell ➝ Neutral
11/23/2020Morgan StanleyReiterated RatingEqual Weight
11/11/2020HSBCUpgradeReduce ➝ Hold
9/29/2020Berenberg BankInitiated CoverageBuy
9/23/2020Oddo BhfUpgradeReduce ➝ Buy
7/29/2020BarclaysReiterated RatingOverweight
6/24/2020Oddo BhfDowngradeBuy ➝ Reduce
6/10/2020CowenBoost Target$55.00 ➝ $60.00
6/4/2020UBS GroupReiterated RatingSell
5/29/2020GuggenheimReiterated RatingBuy
5/29/2020Leerink PartnersBoost TargetOutperform$60.00 ➝ $65.00
5/6/2020Morgan StanleyReiterated RatingEqual Weight
5/6/2020ArgusBoost TargetBuy$54.00 ➝ $60.00
5/1/2020GuggenheimReiterated RatingBuy
4/27/2020BarclaysReiterated RatingOverweight
4/23/2020FIG PartnersInitiated CoverageReduce
4/15/2020Morgan StanleyReiterated RatingEqual Weight
2/28/2020CowenReiterated RatingBuy$55.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.04 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 39 very positive mentions
  • 57 positive mentions
  • 10 negative mentions
  • 4 very negative mentions
Mentions as of
5/25/2024
  • 35 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 27 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 36 very positive mentions
  • 40 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
Mentions as of
8/23/2024
  • 36 very positive mentions
  • 40 positive mentions
  • 13 negative mentions
  • 8 very negative mentions
Mentions as of
9/22/2024
  • 39 very positive mentions
  • 18 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
10/22/2024
  • 58 very positive mentions
  • 60 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
Mentions as of
11/21/2024
  • 67 very positive mentions
  • 33 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 67 very positive mentions
  • 33 positive mentions
  • 1 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

AstraZeneca logo
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $65.35
Low: $63.75
High: $65.46

50 Day Range

MA: $69.02
Low: $63.20
High: $78.31

52 Week Range

Now: $65.35
Low: $60.47
High: $87.68

Volume

9,077,313 shs

Average Volume

5,342,888 shs

Market Capitalization

$202.63 billion

P/E Ratio

31.27

Dividend Yield

1.52%

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of AstraZeneca?

The following equities research analysts have issued reports on AstraZeneca in the last year: Argus, Barclays PLC, BMO Capital Markets, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Erste Group Bank AG, Jefferies Financial Group Inc., Morgan Stanley, TD Cowen, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for AZN.

What is the current price target for AstraZeneca?

0 Wall Street analysts have set twelve-month price targets for AstraZeneca in the last year. Their average twelve-month price target is $89.75, suggesting a possible upside of 37.3%. The Goldman Sachs Group, Inc. has the highest price target set, predicting AZN will reach $97.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $82.00 for AstraZeneca in the next year.
View the latest price targets for AZN.

What is the current consensus analyst rating for AstraZeneca?

AstraZeneca currently has 3 hold ratings, 6 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AZN.

What other companies compete with AstraZeneca?

Other companies that are similar to AstraZeneca include Novo Nordisk A/S, Novartis, Sanofi, GSK and Takeda Pharmaceutical. Learn More about companies similar to AstraZeneca.

How do I contact AstraZeneca's investor relations team?

AstraZeneca's physical mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company's listed phone number is 442037495000 and its investor relations email address is [email protected]. The official website for AstraZeneca is www.astrazeneca.com. Learn More about contacing AstraZeneca investor relations.